Immune responses to CRISPR-Cas protein

Roy, Sudip

doi:10.1016/bs.pmbts.2020.12.003

Cited by 3 publications

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Exploring Advanced CRISPR Delivery Technologies for Therapeutic Genome Editing

Rostami,

Gomari,

Choupani

et al. 2024

Small Science

View full text Add to dashboard Cite

The genetic material within cells plays a pivotal role in shaping the structure and function of living organisms. Manipulating an organism's genome to correct inherited abnormalities or introduce new traits holds great promise. Genetic engineering techniques offers promising pathways for precisely altering cellular genetics. Among these methodologies, clustered regularly interspaced short palindromic repeat (CRISPR), honored with the 2020 Nobel Prize in Chemistry, has garnered significant attention for its precision in editing genomes. However, the CRISPR system faces challenges when applied in vivo, including low delivery efficiency, off‐target effects, and instability. To address these challenges, innovative technologies for targeted and precise delivery of CRISPR have emerged. Engineered carrier platforms represent a substantial advancement, improving stability, precision, and reducing the side effects associated with genome editing. These platforms facilitate efficient local and systemic genome engineering of various tissues and cells, including immune cells. This review explores recent advances, benefits, and challenges of CRISPR‐based genome editing delivery. It examines various carriers including nanocarriers (polymeric, lipid‐derived, metallic, and bionanoparticles), viral particles, virus‐like particles, and exosomes, providing insights into their clinical utility and future prospects.

show abstract

Exploring Advanced CRISPR Delivery Technologies for Therapeutic Genome Editing

Rostami,

Gomari,

Choupani

et al. 2024

Small Science

View full text Add to dashboard Cite

show abstract

CRISPR-Cas: Effectors, mechanism, and classification

Alqahtani,

Mahmoud,

Al Deabel

et al. 2024

CRISPRized Horticulture Crops

View full text Add to dashboard Cite

Targeting DLBCL by mutation-specific disruption of cancer-driving oncogenes

Heshmatpour,

Kazemi,

Schmidt

et al. 2024

Front. Genome Ed.

View full text Add to dashboard Cite

Diffuse large B cell lymphomas (DLBCL) are highly aggressive tumors. Their genetic complexity and heterogeneity have hampered the development of novel approaches for precision medicine. Our study aimed to develop a personalized therapy for DLBCL by utilizing the CRISPR/Cas system to induce knockouts (KO) of driver genes, thereby causing cancer cell death while minimizing side effects. We focused on OCI-LY3 cells, modeling DLBCL, and compared them with BJAB cells as controls. Analysis of whole exome sequencing revealed significant mutations in genes like PAX5, CD79B, and MYC in OCI-LY3 cells. CRISPR/Cas9-mediated KO of these genes resulted in reduced cancer cell viability. Subsequent single and dual gRNA targeting of PAX5 mutations inhibited proliferation specifically in OCI-LY3 cells. Moreover, dual gRNA targeting of PAX5 and MYC induced chromosomal rearrangements, reducing cell proliferation substantially. However, targeting single intronic mutations did not affect cell viability, highlighting the importance of disrupting protein function. Targeting multiple mutations simultaneously addresses intra-tumoral heterogeneity, and the transient delivery of CRISPR/Cas9 allows for permanent gene disruption. While challenges such as incomplete editing efficiency and delivery limitations exist, further optimization may enhance therapeutic efficacy. Overall, our findings demonstrate the efficacy of CRISPR/Cas9 in targeting oncogenic mutations, opening avenues for precision medicine in DLBCL treatment.

show abstract

Immune responses to CRISPR-Cas protein

Cited by 3 publications

References 37 publications

Exploring Advanced CRISPR Delivery Technologies for Therapeutic Genome Editing

Exploring Advanced CRISPR Delivery Technologies for Therapeutic Genome Editing

CRISPR-Cas: Effectors, mechanism, and classification

Targeting DLBCL by mutation-specific disruption of cancer-driving oncogenes

Contact Info

Product

Resources

About